Heidrick & Struggles International, Inc. (NASDAQ:HSII – Get Free Report) announced a quarterly dividend on Monday, November 4th, RTT News reports. Stockholders of record on Thursday, November 14th will be paid a dividend of 0.15 per share by the business services provider on Thursday, November 21st. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.50%.
Heidrick & Struggles International has a payout ratio of 21.1% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Heidrick & Struggles International to earn $2.85 per share next year, which means the company should continue to be able to cover its $0.60 annual dividend with an expected future payout ratio of 21.1%.
Heidrick & Struggles International Price Performance
HSII stock traded up $0.65 during trading on Monday, hitting $39.93. 89,757 shares of the company traded hands, compared to its average volume of 151,316. Heidrick & Struggles International has a 1 year low of $24.90 and a 1 year high of $41.94. The company has a market cap of $811.38 million, a PE ratio of 21.01, a P/E/G ratio of 0.93 and a beta of 0.85. The stock’s 50-day simple moving average is $37.90 and its 200 day simple moving average is $35.32.
Wall Street Analysts Forecast Growth
Check Out Our Latest Report on Heidrick & Struggles International
About Heidrick & Struggles International
Heidrick & Struggles International, Inc, together with its subsidiaries, provides executive search, consulting, and on-demand talent services to businesses and business leaders worldwide. It enables its clients to build leadership teams by facilitating the recruitment, management, and development of senior executives.
Recommended Stories
- Five stocks we like better than Heidrick & Struggles International
- Investing in the High PE Growth Stocks
- Intel: Is Now the Time to Be Brave?Â
- Conference Calls and Individual Investors
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Heidrick & Struggles International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heidrick & Struggles International and related companies with MarketBeat.com's FREE daily email newsletter.